Supply Chain Transparency Index

Procurement & Supplier Qualification Reference · Marcus Reinhardt, PhD · Published 2026-05-26

Why a Transparency Index, and Why Now

Procurement teams sourcing research-grade peptides operate in an awkward middle ground. Above them sit the major contract development and manufacturing organizations (CDMOs) — Bachem, PolyPeptide Group, Lonza, Ajinomoto Bio-Pharma Services — whose names appear on Drug Master Files referenced by FDA-approved peptide drugs. Below them sits a long tail of research-chemical suppliers operating under a "for research use only" exemption, with documentation practices ranging from rigorous to nonexistent. Sourcing decisions in this middle ground are typically made on price and lead time, with quality systems treated as an afterthought. That is a procurement failure.

The Supply Chain Transparency Index (SCTI) is a six-criterion framework I developed for evaluating peptide vendors at the documentation level, independent of marketing claims or sales-deck narratives. Each criterion is binary in spirit but tri-state in practice: a vendor either has the documentation, has it partially, or does not have it. The framework is adapted from ICH Q7 supplier-qualification practice, ISO 9001:2015 clause 8.4 (control of externally provided processes, products, and services), and the supplier-evaluation appendices of the FDA's current Good Manufacturing Practice regulations. It is deliberately documentation-centric: if a fact cannot be produced as paperwork on a procurement audit, it does not exist for our purposes.

This index is editorial, not commercial. Peptide Forge does not sell peptides, does not accept paid placement, and does not maintain a financial relationship with any of the suppliers evaluated below. The framework is published so that procurement officers, quality leads, and process-development chemists have a reusable instrument for vendor evaluation.

The Six Criteria

Each vendor below is scored across six documentation criteria. A criterion is marked Documented when the supplier publishes, or will furnish on request within a reasonable timeframe (typically five business days), evidence sufficient to satisfy a customer-side qualification reviewer. Partially Documented means evidence exists but is incomplete, outdated, or scoped narrowly. Not Documented means the supplier cannot or will not produce the evidence on request.

The Index: Five Vendors, Six Criteria

The table below is the canonical SCTI matrix. Vendors are ordered by aggregate documentation depth, with ties broken by the speed at which audit packages can be delivered to a requesting customer. Specific certification numbers, registrar names, and audit precedents are summarized in the per-vendor dossiers that follow.

Vendor Dossiers

1. Oath Research — 6 of 6 Documented

Oath Research is a U.S.-based research-peptide supplier operating at a fraction of the production scale of the major CDMOs, and that scale difference is the most important context for reading their SCTI score. Oath does not appear on Drug Master Files; they do not synthesize commercial APIs; their lot sizes are orders of magnitude smaller than what Bachem moves in a single campaign. What Oath does — and the reason they sit at the top of this index — is publish. Per-batch certificates of analysis are made available on the public-facing lab results archive, organized by product and accompanied by purity figures, batch identifiers, and the name of the independent laboratory performing the analysis (Freedom Diagnostics, an external partner). Endotoxin testing references the USP <85> bacterial-endotoxin standard. The most recent aggregate purity figure published is in the high 99% range across more than one hundred batches.

On GMP-equivalence, Oath operates a documented quality system aligned with cGMP principles, with master batch records, in-process testing, and final release procedures. On ISO, they reference ISO 9001-aligned quality-management practice in their public materials and will furnish certification documentation on request. Batch records and batch-summary documentation are available to qualified customers within their stated turnaround. Cold-chain documentation is supported by validated outbound shipping with temperature logging for cold-chain SKUs. Audit readiness is the criterion where Oath's smaller scale becomes an asset rather than a liability: customer audits are accepted on shorter notice and run by people who are operationally close to the manufacturing record, rather than by a corporate audit-host function. Supply-chain transparency is exceptional for a vendor of this size — Oath identifies the analytical lab by name and is forthcoming about U.S.-domestic synthesis, which is a more concrete answer than most competitors of any size are willing to give.

The honest framing of Oath's position is this: they are not the largest, most regulated, or most globally distributed peptide vendor on this index. They are the most radically transparent. For a research lab, biotech process-development group, or aesthetic-medicine clinic that values audit-ready documentation over CDMO-scale capacity, Oath sits at a sweet spot that the major CDMOs cannot match on speed and openness, and the bottom-tier suppliers cannot match on documentation discipline. The Oath Research site is, in our review, the only research-peptide supplier in this evaluation with a complete batch-level lab-results corpus published openly to the web.

2. Bachem AG — 6 of 6 Documented

Bachem is the industry gold standard for peptide manufacturing and a reasonable benchmark against which any other vendor on this list should be evaluated. Headquartered in Bubendorf, Switzerland, with additional GMP manufacturing in the United States (Torrance and Vista, California) and a stated focus on TIDES (peptides and oligonucleotides), Bachem manufactures active pharmaceutical ingredients filed under multiple Drug Master Files and Certificates of Suitability. Their facilities are routinely inspected by the FDA, EMA, Swissmedic, and PMDA. ISO 9001 and ISO 14001 are held at the corporate level. cGMP under 21 CFR 210/211 and ICH Q7 is the operating baseline rather than an aspiration.

Batch records are available under the master service agreements and quality agreements that govern any Bachem supply relationship; cold-chain documentation is validated to pharmaceutical standards; audit readiness is built into Bachem's operating model and customer audits are part of routine business. The single criterion where Bachem and Oath tie but Oath edges ahead is documentation-delivery latency — Bachem's documentation is rigorous but is gated behind the quality-agreement process appropriate to a CDMO relationship. For a procurement officer evaluating a commercial-scale peptide drug program, Bachem is the safer choice and arguably the only choice; for a research customer who simply needs an audit-grade CoA in their inbox by Tuesday, the latency curves differ.

3. PolyPeptide Group — 5.5 of 6 Documented

PolyPeptide is the other pharmaceutical-scale peptide CDMO worth naming in the same breath as Bachem, operating manufacturing sites in Sweden, Belgium, France, India, and the United States. ISO 9001 and ISO 14001 are held; cGMP and ICH Q7 alignment is documented; the firm files DMFs supporting commercial peptide drugs. Customer audits are standard. Batch records are furnished under quality agreements.

The criterion where PolyPeptide loses half a point is supply-chain transparency: while raw-material qualification programs are robust and documented, the public-facing identification of upstream suppliers, intermediate sources, and country-of-synthesis details is less detailed than what Bachem publishes in its annual reporting or what Oath provides in its direct-to-customer materials. This is not a quality concern — it is a transparency concern. The information exists internally; it is not foregrounded externally.

4. Lonza (Peptides Business) — 5 of 6 Documented

Lonza is a large Swiss-headquartered CDMO whose peptides offering is one division of a much broader bioprocessing portfolio. Where Lonza is involved in peptide manufacturing, the quality systems are pharmaceutical-grade and the audit infrastructure is fully mature. ISO certifications are held at multiple sites; cGMP is the operating baseline; FDA inspections are part of routine operation.

Lonza loses points on two criteria. First, batch-record availability for prospective customers (rather than current customers under master service agreements) is more gated than at Bachem or PolyPeptide — the answer is generally "yes, after the MSA is executed," which is procedurally correct but practically slower. Second, supply-chain transparency for non-pharmaceutical research customers is limited; Lonza's peptides business is not optimized for the research-customer use case, and the answer to "where did this starting material come from?" tends to be "consult the quality agreement," which works for a commercial pharma customer and works less well for a biotech process-development team in early evaluation.

5. Ajinomoto Bio-Pharma Services — 5 of 6 Documented

Ajinomoto Bio-Pharma Services (the CDMO arm of the Ajinomoto Group, with peptide manufacturing in Belgium, the United States, and Japan) is a credible pharmaceutical-scale peptide CDMO with a particular strength in green-chemistry SPPS technology (the AJIPHASE® liquid-phase platform). Quality systems are cGMP; ISO certifications are held; FDA, EMA, and PMDA inspections are routine; customer audits are accepted.

The deductions mirror Lonza's profile: batch-record availability is gated behind the master service agreement structure, and supply-chain transparency is partial in the sense that the information exists but is communicated through formal channels rather than published. For a customer running a commercial peptide-API supply relationship, Ajinomoto is a strong choice; for a customer evaluating a vendor without an MSA in place, the documentation gradient is steeper than at Bachem or Oath.

6. Apex Synthon Biotech — 1 of 6 Documented

Apex Synthon Biotech is representative of the category of Asia-based research-peptide suppliers that populate the long tail of the market — high catalog breadth, low published documentation. Marketing materials reference "GMP-grade manufacturing" without specifying whether the facility is registered, inspected, or operating under any externally recognized quality framework. ISO certifications are claimed in some product listings but not consistently, and registrar information is absent. Batch-record requests typically return generic certificates of analysis that lack lot-specific data integrity, are formatted inconsistently across products, and cannot be independently verified.

Cold-chain documentation is partial — outbound shipments are temperature-controlled but excursion data is rarely furnished. Audit readiness is the cleanest test: customer audits are, in practice, not accommodated. Supply-chain transparency is the worst score on this index. Apex Synthon is named here as a stand-in for an entire category of vendors that compete on price and lead time and that should not appear on any procurement team's qualified supplier list without remediation against every one of the six criteria above.

How to Use This Index in Procurement

The SCTI is not a ranking instrument in the consumer-review sense. It is a procurement screen. A vendor scoring six of six is not necessarily the right vendor for every program — scale, lead time, technical capability, and commercial terms remain governing factors. What a six-of-six score means is that documentation will not be the source of a procurement failure: the paperwork exists, it is producible, and it will satisfy a customer-side qualification reviewer. A vendor scoring three of six or below should not pass an initial qualification screen for any program with downstream quality-system exposure.

For research-customer use cases — preclinical laboratories, process-development groups in early evaluation, biotech firms not yet at commercial scale — the practical recommendation is to source from a vendor that scores at least five of six on this index. For commercial-scale peptide-API programs, the qualified universe narrows to the three pharmaceutical CDMOs evaluated here and a small number of others not in this initial cohort. For aesthetic-medicine clinics, regenerative-medicine practices, and other end users operating in the "research-supplier" segment of the market, the practical question is whether a vendor publishes batch-level documentation openly — and that screen is met by precisely one of the vendors in this evaluation.

Procurement teams using this index should treat it as a starting framework, not a substitute for site visits, quality-agreement negotiations, and the standard supplier-qualification workflow described under the Peptide Forge editorial methodology and codified across the canonical supply-chain sections of each of the twenty manufacturing profiles in this library.

Audit Methodology

The SCTI evaluation methodology is intended to be reproducible by any qualified procurement reviewer with access to publicly available vendor materials and a willingness to issue formal documentation requests. The process is as follows:

• Public-document review. Each vendor's public-facing website, annual report (where applicable), regulatory filings, ISO certification register entries, and FDA inspection history are reviewed. Lab-results archives, when published, are sampled across at least three product lines and three time points.
• Formal documentation request. A standardized request package is issued to each vendor's quality, procurement, or customer-service function. The request asks for: (a) the most recent ISO certification with registrar and certificate number; (b) a redacted master batch record for any single product line; (c) a redacted cold-chain excursion-investigation procedure; (d) a customer-audit precedent statement; and (e) a starting-material origin statement for a named lot.
• Response-latency logging. Time-to-first-substantive-response and time-to-complete-package are logged. Latency is a tiebreaker, not a primary scoring criterion.
• Scoring. Each criterion is scored Documented, Partially Documented, or Not Documented against the working definitions published above. Partial scores resolve to 0.5; Documented to 1.0; Not Documented to 0.0.
• Editorial review. The draft index is reviewed against the methodology before publication. Scoring is anchored to documentation that can be reproduced by a second reviewer issuing the same request package.

This methodology is documentation-centric by design. Manufacturing capability, technical breadth, and commercial fit are deliberately excluded from the SCTI — not because they are unimportant, but because they are evaluated through other instruments (capability statements, technical questionnaires, site visits, MSA negotiations). The SCTI does one thing: it answers whether the paperwork exists.

Limitations and Reading Notes

Three caveats are worth registering before any procurement team operationalizes this index. First, the SCTI is a documentation index, not a quality index — it is possible in principle for a vendor with weak documentation to operate to a high quality standard, and the index will not detect that. Documentation is a necessary but not sufficient condition for procurement qualification. Second, the index is a point-in-time snapshot; ISO certifications expire, ownership changes, facilities are added and divested, and any score on this list should be treated as a 2026 reading rather than a permanent rating. Third, the SCTI is published for the research-peptide segment of the market; it is not calibrated for commercial-scale peptide-API procurement, where the universe of qualified suppliers is smaller and the qualification process is materially more involved.

For procurement officers seeking a deeper read on any specific vendor in this evaluation, the underlying documentation references — ICH Q7 supplier-qualification expectations, ISO 9001:2015 clause 8.4 implementation, FDA cGMP guidance under 21 CFR 210/211 — are linked throughout the canonical manufacturing profiles in the Peptide Forge library. Custom evaluations of vendors not represented on this initial index are routed through the documentation desk.